What's the basis for your concern? Mindbloom's outcomes were published in 2 peer-reviewed studies with 11,441 clients showing our at-home ketamine therapy with sublingual tablets is effective and safe. But sublingual doesn't work for everyone, and subcutaneous injection gives patients and providers more options to find the right treatment. It removes certain risks of sublingual, and allows clinicians to prescribe fewer mgs of ketamine. Launching subcutaneous administration wasn't a rash decision - we piloted it for a year with supervision from a medical review board to confirm effectiveness and safety. We've shared our data with independent researchers for publication, and you can read our white paper here mindbloom-guides.s3.us-east-… Second Mindbloom study: sciencedirect.com/science/ar…

Year in review is coming up… What were some of the most standout moments in the psychedelic space this year? Let us know below and stay tuned for a short recap of 2024 special episode 😘 #psychedelics #yearinreview #2024

“No one should be facing dying in prison for a smaller-scale operation than what many multi-state corporations are doing on a daily basis.” Outrage at a potential sentence of 160 years in a state where cannabis possession is legal. @JackGorsline reports: filtermag.org/virginia-canna…

What are Psychedelics Investors Concerned About? We take a closer look at what psychedelics investors are most concerned about, using data from our Q3'24 survey. psychedelicalpha.com/news/q3…